Comparative Pharmacology
Head-to-head clinical analysis: ENBREL versus HADLIMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBREL versus HADLIMA.
ENBREL vs HADLIMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNF, including changes in adhesion molecules and apoptosis.
50 mg subcutaneous injection once weekly
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
None Documented
None Documented
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Terminal elimination half-life approximately 2 weeks (12-16 days); supports every-2-week dosing in maintenance therapy.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Renal: 0.1-0.5% as unchanged drug in urine; biliary/fecal: 70-90% as metabolites; mostly via reticuloendothelial system degradation.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor